Affiliation:
1. Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust , Cambridge , UK
Abstract
Abstract
Thiopurines remain an important option in the treatment of IBD. However, the unpredictable and sometimes serious side effects and intolerance remain a major challenge. Pretreatment of extended genetic panel analysis, identification of novel variants, and monitoring of intermediate metabolites will help improve the overall outcome and reduce the toxicity.
Publisher
Oxford University Press (OUP)